General Information of DTT (ID: TTL4Q97)

DTT Name Cyclin-dependent kinase 5 (CDK5) DTT Info
Gene Name CDK5

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Preclinical Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Investigative Drug(s)
8 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN N. A. N. A. Patented [1]
Flavonoid derivative 7 DM6A9UR N. A. N. A. Patented [1]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [2]
Naphthyridine and isoquinoline derivative 1 DMTGIP7 N. A. N. A. Patented [1]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [1]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW N. A. N. A. Patented [1]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [1]
Tricyclic benzimidazole derivative 1 DM5SD9E N. A. N. A. Patented [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Patented Agent(s)
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-751250 DMOERXK Obesity 5B81 Preclinical [3]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Olomoucine DMNAFG1 N. A. N. A. Terminated [3]
------------------------------------------------------------------------------------
16 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea DMJVITG Discovery agent N.A. Investigative [4]
10Z-Hymenialdisine DMIRSA5 Discovery agent N.A. Investigative [3]
3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one DMQC9WV Discovery agent N.A. Investigative [5]
9-Nitropaullone DM8LUYM Discovery agent N.A. Investigative [3]
aloisine A DM5U1LN Discovery agent N.A. Investigative [6]
aminopurvalanol A DMKLC3O N. A. N. A. Investigative [7]
AZAKENPAULLONE DM61H07 Discovery agent N.A. Investigative [2]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [3]
Indirubin-5-sulfonate DM08VHZ Discovery agent N.A. Investigative [3]
MANZAMINE A DMB3GNC Discovery agent N.A. Investigative [8]
NU6140 DMCUSG3 Discovery agent N.A. Investigative [9]
Oxindole 16 (compound 3) DMM5208 Discovery agent N.A. Investigative [3]
Oxindole 95 DM4UL1G Discovery agent N.A. Investigative [3]
Quinoxaline1 DMRWXH4 Discovery agent N.A. Investigative [7]
SU9516 DMQHG0R Discovery agent N.A. Investigative [3]
Thieno analogue of kenpaullone DMIOTHG Discovery agent N.A. Investigative [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
3 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
4 Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem. 2007 Oct 15;15(20):6574-95.
5 Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9.
6 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
7 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
8 Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
9 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.